Citations

Clear

4 citation(s) found for "Pascual, Julio".

International consensus on post-transplantation diabetes mellitus
Sharif, Adnan , Vries, Aiko P. J. de , Eller, Kathrin , Guthoff, Martina , Haller, Maria , Nordheim, Espen , Kautzky‐Willer, Alexandra , Krebs, Michael , Kukla, Aleksandra , Kurnikowski, Amelie , Schwaiger, Elisabeth , Jenssen, Trond , de Vries, Aiko P J , Eller, Kathrin , Guthoff, Martina , Haller, Maria C , Nordheim, Espen , Krebs, Michael , Montero, Nuria , Pascual, Julio , Hecking, Manfred , Kautzky-Willer, Alexandra , Chakkera, Harini A. , Hornum, Mads , Porrini, Esteban

Mayo Clinic

Nephrology Dialysis Transplantation | December 8, 2023 | Volume: 39 | Issue: 3 | Pages: 531-549

10.1093/ndt/gfad258 | PMID 38171510 Get It

ABSTRACT Post-transplantation diabetes mellitus (PTDM) remains a leading complication after solid organ transplantation. Previous international PTDM consensus meetings in 2003 and 2013 provided standardized frameworks to reduce heterogeneity in diagnosis, risk stratification and management. However, the last decade has seen significant advancements in our PTDM knowledge complemented by rapidly changing treatment algorithms for management of diabetes in the general population. In view of these developments, and to ensure reduced variation in clinical practice, a 3rd international PTDM Consensus Meeting was planned and held from 6–8 May 2022 in Vienna, Austria involving global delegates with PTDM expertise to update the previous reports. This update includes opinion statements concerning optimal diagnostic tools, recognition of prediabetes (impaired fasting glucose and/or impaired glucose tolerance), new mechanistic insights, immunosuppression modification, evidence-based strategies to prevent PTDM, treatment hierarchy for incorporating novel glucose-lowering agents and suggestions for the future direction of PTDM research to address unmet needs. Due to the paucity of good quality evidence, consensus meeting participants agreed that making GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) recommendations would be flawed. Although kidney-allograft centric, we suggest that these opinion statements can be appraised by the transplantation community for implementation across different solid organ transplant cohorts. Acknowledging the paucity of published literature, this report reflects consensus expert opinion. Attaining evidence is desirable to ensure establishment of optimized care for any solid organ transplant recipient at risk of, or who develops, PTDM as we strive to improve long-term outcomes.
How does the brain change in chronic migraine? Developing disease biomarkers
Coppola, Gianluca , Coppola, Gianluca , Pozo‐Rosich, Patricia , Pascual, Julio , Schwedt, Todd J.

Mayo Clinic

Cephalalgia | December 10, 2020 | Volume: 41 | Issue: 5 | Pages: 613-630

10.1177/0333102420974359 | PMID 33291995 Get It

Background Validated chronic migraine biomarkers could improve diagnostic, prognostic, and predictive abilities for clinicians and researchers, as well as increase knowledge on migraine pathophysiology. Objective The objective of this narrative review is to summarise and interpret the published literature regarding the current state of development of chronic migraine biomarkers. Findings Data from functional and structural imaging, neurophysiological, and biochemical studies have been utilised towards the development of chronic migraine biomarkers. These biomarkers could contribute to chronic migraine classification/diagnosis, prognosticating patient outcomes, predicting response to treatment, and measuring treatment responses early after initiation. Results show promise for using measures of brain structure and function, evoked potentials, and sensory neuropeptide concentrations for the development of chronic migraine biomarkers, yet further optimisation and validation are still required. Conclusions Imaging, neurophysiological, and biochemical changes that occur with the progression from episodic to chronic migraine could be utilised for developing chronic migraine biomarkers that might assist with diagnosis, prognosticating individual patient outcomes, and predicting responses to migraine therapies. Ultimately, validated biomarkers could move us closer to being able to practice precision medicine in the field and thus improve patient care.
Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults
Silberstein, Stephen D., Tfelt‐Hansen, Peer , Dodick, DW, Limmroth, Volker , Lipton, RB, Wang, S. J., Lipton, RB, Pascual, Julio

Mayo Clinic

Cephalalgia | February 20, 2008 | Volume: 28 | Issue: 5 | Pages: 484-495

10.1111/j.1468-2982.2008.01555.x | PMID 18294250 Get It

In 1991 the Clinical Trials Subcommittee of the International Headache Society (IHS) developed and published its first edition of the Guidelines on controlled trials of drugs in episodic migraine because only quality trials can form the basis for international collaboration on drug therapy, and these Guidelines would ‘improve the quality of controlled clinical trials in migraine’. With the current trend for large multinational trials, there is a need for increased awareness of methodological issues in clinical trials of drugs and other treatments for chronic migraine. These Guidelines are intended to assist in the design of well-controlled clinical trials of chronic migraine in adults, and do not apply to studies in children or adolescents.